Showing results (81-90 of 223) with videos related to

Sort By:
Pageof 23
Cancers|April 3, 2021
Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer PatientsMarta Sanz-Álvarez, Ion Cristóbal, Melani Luque, et al.
Oncotarget|March 2, 2015
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effectsRaúl Rincón, Ion Cristóbal, Sandra Zazo, et al.
International Journal of Molecular Sciences|December 24, 2021
Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast CancerMelani Luque, Marta Sanz-Álvarez, Andrea Santamaría, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2006
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinomaFederico Rojo, Josep Tabernero, Joan Albanell, et al.
World Journal of Surgery|May 26, 2018
Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer PatientsBlanca Torrejón, Ion Cristóbal, Cristina Caramés, et al.
Molecular Cancer Therapeutics|January 23, 2014
PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potentialIon Cristóbal, Rebeca Manso, Raúl Rincón, et al.
Critical Reviews in Oncology/Hematology|July 1, 2026
Gene Fusions in Non-small cell lung carcinoma (NSCLC): Expert Perspectives and Practical Considerations for routine testingBeatriz Bellosillo, Javier Freire, Ihab Abdulkader Nallib, et al.
Journal of Clinical Pathology|December 15, 2010
Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancerRobin L Jones, Federico Rojo, Roger A'Hern, et al.
The Lancet. Oncology|October 18, 2017
Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trialRobert Coleman, Andrew Hall, Joan Albanell, et al.
Cancers|June 26, 2020
MicroRNA-199b Downregulation Confers Resistance to 5-Fluorouracil Treatment and Predicts Poor Outcome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer PatientsIon Cristóbal, Jaime Rubio, Andrea Santos, et al.
Pageof 23